Facebook
Twitter
LinkedIn
ForwardCOVID-19 Pharmacy Practice Considerations Series - Multisystem Inflammatory Syndrome in Children in COVID-19: Diagnosis, Management, and Relationship to Kawasaki Disease
The educational series will provide resources and updated guidance for pharmacists and pharmacy technicians on the pharmacy practice considerations needed for the management of COVID-19 patients, including shortage mitigation, pharmacotherapy options, emergency preparedness, and medication safety.
Target Audience
Pharmacist
Pharmacy Tech
Learning Objectives
Pharmacist
1. Describe Multisystem Inflammatory Syndrome in Children (MIS-C) and the timing of its onset in relation to SARS-CoV-2 infection.
2. Explain the mechanisms by which viruses can induce autoimmune reactions and the role of immunomodulating agents in the management of MIS-C.
3. Outline Kawasaki disease diagnosis and treatment, relating to MIS-C.
4. Identify ongoing research for pediatric inflammatory syndromes.
Pharmacy Tech
1. Identify immunomodulators that have a potential role in the management of MIS-C.
2. Recall dosing, labeling, and administration information for IVIG.
Additional Information
| Attachment | Size |
|---|---|
 Information for CE | 124.92 KB |
| Helpful Tips for Users | 23.36 KB |
 Presentation | 6.25 MB |
Relevant financial relationships: None of the planning committee have anything to disclose.
Michael Portman will discuss off-label use of drugs and investigative use of drugs. Please describe: Use of TNF antagonists such as Etanercept and Infliximab for Kawasaki Disease.
Michelle Rychalsky will discuss off-label use of drugs. Please describe: I will discuss the role of interleukin-1 and interleukin-6 inhibitors (e.g. anakinra, tocilizumab), as well as corticosteroids, for management of Multisystem Inflammatory Syndrome in Children (MIS-C). I will discuss investigative use of drugs. Please describe: I will mention that remdesivir is an antiviral currently available via compassionate and emergency use, and that is currently being studied, for management of SARS-CoV-2 infection in children.
Planning committee members
Jackie Stokes, BS
Manager, Pharmacy Program Services
Vizient
Gretchen Brummel
PharmD, BCPS
Pharmacy Executive Director
Vizient
Katrina Harper
PharmD, MBA, BCPS, BCSCP
Clinical Pharmacy Director
Vizient
Course reviewer
Katrina Harper
PharmD, MBA, BCPS, BCSCP
Clinical Pharmacy Director
Vizient
Presenters
Michael A. Portman, MD
Director, Pediatric Cardiovascular Research
Professor of Pediatrics
Seattle Children’s Hospital
Michelle Rychalsky, PharmD, BCPS
Senior Clinical Pharmacy Specialist
Yale New Haven Children's Hospital
Joint Accreditation Statement:
In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Designation Statements:
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
JA0006103-0000-20-103-L04-P - JA0006103-0000-20-103-L04-T
CEU
Vizient, Inc. will award CEUs to each participant who successfully completes this program. The CEU is a nationally recognized unit of measure for continuing education and training programs that meet certain criteria (1 contact hour = 0.1 CEU).
Available Credit
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician
- 1.00 General CE – Attendance